In Segment A, members will receive diverse doses and schedules of oral ABBV-744 pill to recognize Protected dosing routine. Additional individuals are going to be enrolled in the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In https://abbv-744preclinicalstudie57801.blog-eye.com/32111753/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc